Actually, results of two large scale researches published in 2017 have manifested the inhibition ANGPTL3 by monoclonal antibody or antisense oligonucleotides can obviously influence the concentration of lipid and reduce the risk of dyslipidemia and CVD. This evidence concerns the gene ANGPTL3 and metabolic syndrome.